S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
- DOI
- 10.1097/01.hs9.0000967776.81028.41
- Published
- 2023-08
- Container
- HemaSphere
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/01.hs9.0000967776.81028.41,
title = {S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY},
author = {Huilai Zhang and Jingwei Yu and He LI and Wenbin Qian and Xibin Xiao and Qingqing Cai and Yao Liu and Yu Zhang and Liling Zhang and Ling Qin and Hui Zhou and Xiaoyi Tang and Yingmei Guo and Hui Zhou and Ting Niu},
year = {2023},
journal = {HemaSphere},
doi = {10.1097/01.hs9.0000967776.81028.41},
url = {https://doi.org/10.1097/01.hs9.0000967776.81028.41}
}RIS
TY - JOUR TI - S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY AU - Huilai Zhang AU - Jingwei Yu AU - He LI AU - Wenbin Qian AU - Xibin Xiao AU - Qingqing Cai AU - Yao Liu AU - Yu Zhang AU - Liling Zhang AU - Ling Qin AU - Hui Zhou AU - Xiaoyi Tang AU - Yingmei Guo AU - Hui Zhou AU - Ting Niu PY - 2023 JO - HemaSphere DO - 10.1097/01.hs9.0000967776.81028.41 UR - https://doi.org/10.1097/01.hs9.0000967776.81028.41 ER -
APA
Zhang, H., Yu, J., LI, H., Qian, W., Xiao, X., Cai, Q., Liu, Y., Zhang, Y., Zhang, L., Qin, L., Zhou, H., Tang, X., Guo, Y., Zhou, H., & Niu, T. (2023). S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY. HemaSphere. https://doi.org/10.1097/01.hs9.0000967776.81028.41
Source records
- crossref · retrieved 2026-09-25T21:30:13.237Z